Untitled Document
The world's poorest people are being denied access to drugs because
pharmaceutical companies are focusing their resources on diseases suffered by
wealthy, middle-aged Americans, such as obesity and heart disease, a leading
expert will say tomorrow.
Dr David Rhodes, the Health Protection Agency's (HPA) head of business
development, will claim that spiralling costs are driving firms to invest primarily
in drugs that tackle diseases of 'older Americans'.
As a result, the international market has been flooded with medicines
to treat 'American diseases' such as high blood pressure, obesity, heart disease
and cancer, while drugs to tackle tuberculosis, malaria and water-borne diseases
prevalent in the poorest countries have been neglected.
Presenting his research at the HPA's annual conference tomorrow, Rhodes will
show that more and more pharmaceutical companies are moving their headquarters
to the US in search of profits. Once there, they pump money into treatments
that help the local population to live longer.
'Drugs and vaccines are becoming phenomenally expensive to develop,' said Rhodes.
'Companies have to recoup their investments by selling the drugs and vaccines.
To be economic, they need a large population and the price has to be high. That
increasingly means that drugs are developed for older Americans, who are getting
healthier and living longer.'
Costs are soaring, added Rhodes, because of extensive safety and efficacy testing
and the fact that many drugs that show 'early promise' never make it through
the checks.
As such, companies looking to be 'economic' shift resources to meet the needs
- and benefit from the profits - of the biggest spenders. 'The US tend to get
the first bite of the cherry,' admitted Rhodes.
He said the trend had led to a 'vicious' circle in the poorest countries of
'low economic growth leading to poor healthcare systems, creating a higher burden
of disease which in turn affects the ability of the population to develop economically'.
But while sub-Saharan Africa is heavily affected, China and India's strong investment
in their pharmaceutical industry has seen health improvements and economic bonuses
that will in turn attract investment back.
Nevertheless, with many private companies turning their back on the developing
world, Rhodes said research was heavily dependent on philanthropic funding and
government backing.
He welcomed the International Finance Facility for Immunisation - the funding
arm of the Global Alliance for Vaccines and Immunisation - that was launched
on Friday. The group has pledged to raise $4 billion (£2.2bn) for an immunisation
programme in the developing world.
